المؤلفون: Aljohani H; Drug Safety and Risk Management Department, Executive Directorate of Pharmacovigilance, Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia. hialjehani@gmail.com., Alrubaish FS; Drug Safety and Risk Management Department, Executive Directorate of Pharmacovigilance, Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia., Alghamdi WM; Drug Safety and Risk Management Department, Executive Directorate of Pharmacovigilance, Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia., Al-Harbi F; Drug Safety and Risk Management Department, Executive Directorate of Pharmacovigilance, Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.

المصدر: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2024 Jul; Vol. 58 (4), pp. 622-633. Date of Electronic Publication: 2024 Apr 18.

نوع المنشور: Journal Article; Meta-Analysis; Systematic Review

بيانات الدورية: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101597411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2168-4804 (Electronic) Linking ISSN: 21684790 NLM ISO Abbreviation: Ther Innov Regul Sci Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/drug therapy , Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use , Dipeptidyl-Peptidase IV Inhibitors*/adverse effects , Linagliptin*/therapeutic use , Linagliptin*/adverse effects , Randomized Controlled Trials as Topic*, Humans ; Cardiovascular Diseases/chemically induced ; Hypoglycemic Agents/therapeutic use ; Hypoglycemic Agents/adverse effects